Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript

SA Transcripts158.83K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call March 5, 2026 4:30 PM EST Company Participants Jonae Barnes - Senior Vice President of Investor Relations & Corporate CommunicationsJean-Pierre Sommadossi - Founder, Chairman, CEO & PresidentJanet Hammond - Chief Development OfficerMaria Horga - Chief Medical OfficerJohn Vavricka - Chief Commercial OfficerAndrea Corcoran - CFO, Executive VP of Legal & Secretary Conference Call Participants Selena Zhang - Morgan Stanley, Research DivisionJonathan Miller - Evercore ISI Institutional Equities, Research DivisionTsan-Yu Hsieh - William Blair & Company L.L.C., Research Division Presentation Operator Good afternoon, everyone, and welcome to the Atea Pharmaceuticals' Fourth Quarter 2025 Financial Results and Business Update Conference Call. [Operator Instructions] I would now like to turn the call over to Jonae Barnes, Senior Vice President of Investor Relations and Corporate Communications at Atea Pharmaceuticals. Ms. Barnes, please proceed. Jonae BarnesSenior Vice President of Investor Relations & Corporate Communications Great. Thank you, operator. Good afternoon, everyone, and welcome to Atea Pharmaceuticals' Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call. Earlier today, we issued a press release, which outlines the topics we plan to discuss. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our website at ir.ateapharma.com. With me today from Atea are our Chief Executive Officer and Founder; Dr. Jean-Pierre Sommadossi; Chief Development Officer, Dr. Janet Hammond; Chief Commercial Officer, John Vavricka; Chief Medical Officer; Dr. Arantxa Horga; and Chief Financial Officer and Executive Vice President of Legal, Andrea Corcoran, who will be available for the Q&A portion of today's call. Before we begin the call and as outlined on Slide 2, I would like to remind you that today's discussion will contain forward-looking statements that involve risks and uncertainties. These